. He can be reached at nsaraceno@mjhlifesciences.com.

Videos

Dave Malenfant, healthcare supply chain expert, outlines the topics that are top of mind at the show.

LogiPharma USA 2025: What Were the Standout Trends?

Podcasts

This episode of Pharma Pulse covers the FDA’s quiet approval of the first generic mifepristone tablet, Takeda’s decision to discontinue cell therapy research programs, and SciSafe’s expansion of biopharma storage capacity with a new East Brunswick, New Jersey facility.

Pharma Pulse: FDA Approves First Generic Mifepristone, Takeda Exits Cell Therapy Research, and SciSafe Expands Biopharma Storage

Articles

The new 5-million-cubic-foot biorepository enhances cold chain logistics, expands biopharma storage capacity, and strengthens New Jersey’s position as a life sciences hub.

SciSafe Expands Biopharma Storage With New East Brunswick Facility

Dave Malenfant, healthcare supply chain expert, reflects on LogiPharma USA’s 20-year evolution, noting its shift toward greater diversity and inclusion, particularly with more women entering the industry.

LogiPharma USA 2025: The Conference's Development Over 20 Years

This episode of Pharma Pulse covers the potential ramifications of a federal government shutdown on FDA operations, Aetna’s newly announced 2026 Medicare Advantage offerings, and new research showing maternal and child mortality rates in the US remain higher than in most high-income nations.

Pharma Pulse: FDA Faces Shutdown Risks, Aetna Unveils 2026 Medicare Advantage Plans, and US Maternal Mortality Remains High

Experts from Moderna, Revelation Pharma, and Alexion offer ways to reduce risks, improve real-time visibility, and ensure product integrity in the growing ship-to-home market.

LogiPharma USA 2025: How Pharma Leaders Are Tackling Temperature Monitoring in Direct-to-Patient Shipments

Dave Malenfant, healthcare supply chain expert, shares his excitement about the strong turnout at LogiPharma USA, noting a packed master class and his role as chair of the “people” track—a personal passion.

LogiPharma USA 2025: Dave Malenfant's Sneak Peek

This episode of Pharma Pulse covers ATA’s warning that telehealth protections are critical to maintaining care access during a potential federal shutdown, new KFF data showing the rapid rise of Medicare Advantage special needs plans, and Halozyme’s $750 million acquisition of Elektrofi to expand its drug delivery portfolio.

Pharma Pulse: Telehealth Access at Risk During Shutdown, Medicare Advantage SNPs Surge, and Halozyme Buys Elektrofi for $750M

How cell and gene therapy developers can lessen the chances of receiving FDA complete response letters through the use of proactive chemistry, manufacturing, and controls strategies.

How Cell and Gene Therapy Developers Can Reduce Risk of FDA Complete Response Letters With Proactive CMC Strategies

Dave Malenfant, healthcare supply chain expert, discusses the ramifications of a 100% tariff on branded and patented drugs entering the US.

News